Bilateral sub-deltoid bursitis in a patient receiving infliximab for Crohn's disease.
We report here a case of inflammatory bursitis in a patient with crohn's disease after switching to biosimilar infliximab. The patient's clinical, biological and imaging data were reviewed as well as the literature on inflammatory bursitis in patients under infliximab therapy. A 41-year-old man with crohn's disease evolving from 3 years was referred to infliximab therapy at a dose of 5mg/kg because of an aggressive resistant perineal fistula. After 14 infusions of infliximab, the treatment was switched to infliximab biosimilar using the same dose and frequency of administration. Forty-eight hours after the second infusion, he developed an acute onset of muscle pain and stiffness on both of his shoulders. A muskuloskeletal ultrasound was performed and revealed a hypoechoic widening of both of subacromial bursae, more severe on the left side. The diagnosis of non infective sub-acromial bursitis secondary to infliximab infusion was made as the patient's symptoms resolved rapidly without any antibiotics. Infliximab was definitively stopped and adalimumab was introduced. Musculoskeletal side effects of inﬂiximab infusion are uncommonly reported. Among them bursitis has been reported in only few cases. Ultrasonography can help early diagnosis of bursitis. The time of occurring of this reaction regarding to infliximab infusion, screening of ATI and clinical outcome after drug discontinuation are the main helpful arguments.